<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04739254</url>
  </required_header>
  <id_info>
    <org_study_id>1000-4</org_study_id>
    <nct_id>NCT04739254</nct_id>
  </id_info>
  <brief_title>Magnetocardiography Endocrine Registry</brief_title>
  <acronym>MACENDOR</acronym>
  <official_title>Magnetocardiography Endocrine Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genetesis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genetesis Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endocrine disorders like Type 2 diabetes mellitus (T2DM) represent complex cardiometabolic&#xD;
      disease processes affecting approximately 462 million individuals worldwide and is associated&#xD;
      with a two- to three-fold increase in cardiovascular mortality. Individuals with T2DM are at&#xD;
      an increased risk of developing cardiovascular disease. Research has shown individuals with&#xD;
      T2DM and no previous history of coronary artery disease are still at similar risk rates for&#xD;
      cardiovascular events as patients with a prior myocardial infarction. The&#xD;
      MAgenetoCardiography ENDOcrine Registry (MACENDOR) study is designed to collect CardioFlux&#xD;
      scans on a select group of volunteers who are high-risk patients with endocrine disorders.&#xD;
      CardioFlux is used as a noninvasive magnetocardiography (MCG) tool that analyzes and records&#xD;
      the magnetic fields of the heart to screen volunteers for heart disease. There will be a&#xD;
      12-month duration of the study where we propose to collect screening data from approximately&#xD;
      250 volunteers who present to the Genetesis facility for a 5-minute CardioFlux scan. The&#xD;
      volunteers will be contacted at intervals over a 1-year period for follow-up data and may&#xD;
      choose whether or not they would like to provide follow-up data or participate in another&#xD;
      scan.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Accuracy statistics</measure>
    <time_frame>12 months</time_frame>
    <description>analyzing the accuracy of CardioFlux</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity statistics</measure>
    <time_frame>12 months</time_frame>
    <description>analyzing the specificity of CardiFlux</description>
  </primary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Endocrine Disorder</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Not an intervention</intervention_name>
    <description>Not an intervention</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are at risk for cardiovascular disease due to endocrine disorders.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ≥ 18 years of age at the time of enrollment&#xD;
&#xD;
          2. Patients deemed at risk for cardiovascular disease from endocrine disorders&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. &lt; 18 years of age&#xD;
&#xD;
          2. Patients unable to fit into device&#xD;
&#xD;
          3. Non-ambulatory patients&#xD;
&#xD;
          4. Positive response(s) on CardioFlux Pre-Screening Form&#xD;
&#xD;
          5. Patients with claustrophobia or unable to lie supine for five minutes&#xD;
&#xD;
          6. Pregnant women&#xD;
&#xD;
          7. Poor candidates for follow-up (e.g., no access to phone)&#xD;
&#xD;
          8. Prisoners&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Senagore, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Genetesis Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anthony Senagore, M.D.</last_name>
    <phone>513-715-5045</phone>
    <email>anthony@genetesis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Samantha Legreaux, M.S.</last_name>
    <phone>513-715-5045</phone>
    <email>sam.legreaux@genetesis.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Genetesis Facility</name>
      <address>
        <city>Mason</city>
        <state>Ohio</state>
        <zip>45040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Legreaux, M.S.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, Cavan D, Shaw JE, Makaroff LE. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017 Jun;128:40-50. doi: 10.1016/j.diabres.2017.03.024. Epub 2017 Mar 31.</citation>
    <PMID>28437734</PMID>
  </reference>
  <reference>
    <citation>Rao Kondapally Seshasai S, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, Njølstad I, Fletcher A, Nilsson P, Lewington S, Collins R, Gudnason V, Thompson SG, Sattar N, Selvin E, Hu FB, Danesh J; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011 Mar 3;364(9):829-841. doi: 10.1056/NEJMoa1008862. Erratum in: N Engl J Med. 2011 Mar 31;364(13):1281.</citation>
    <PMID>21366474</PMID>
  </reference>
  <reference>
    <citation>Emerging Risk Factors Collaboration, Di Angelantonio E, Kaptoge S, Wormser D, Willeit P, Butterworth AS, Bansal N, O'Keeffe LM, Gao P, Wood AM, Burgess S, Freitag DF, Pennells L, Peters SA, Hart CL, Håheim LL, Gillum RF, Nordestgaard BG, Psaty BM, Yeap BB, Knuiman MW, Nietert PJ, Kauhanen J, Salonen JT, Kuller LH, Simons LA, van der Schouw YT, Barrett-Connor E, Selmer R, Crespo CJ, Rodriguez B, Verschuren WM, Salomaa V, Svärdsudd K, van der Harst P, Björkelund C, Wilhelmsen L, Wallace RB, Brenner H, Amouyel P, Barr EL, Iso H, Onat A, Trevisan M, D'Agostino RB Sr, Cooper C, Kavousi M, Welin L, Roussel R, Hu FB, Sato S, Davidson KW, Howard BV, Leening MJ, Leening M, Rosengren A, Dörr M, Deeg DJ, Kiechl S, Stehouwer CD, Nissinen A, Giampaoli S, Donfrancesco C, Kromhout D, Price JF, Peters A, Meade TW, Casiglia E, Lawlor DA, Gallacher J, Nagel D, Franco OH, Assmann G, Dagenais GR, Jukema JW, Sundström J, Woodward M, Brunner EJ, Khaw KT, Wareham NJ, Whitsel EA, Njølstad I, Hedblad B, Wassertheil-Smoller S, Engström G, Rosamond WD, Selvin E, Sattar N, Thompson SG, Danesh J. Association of Cardiometabolic Multimorbidity With Mortality. JAMA. 2015 Jul 7;314(1):52-60. doi: 10.1001/jama.2015.7008. Erratum in: JAMA. 2015 Sep 15;314(11):1179. Leening, Maarten [corrected to Leening, Maarten J G].</citation>
    <PMID>26151266</PMID>
  </reference>
  <reference>
    <citation>Tancredi M, Rosengren A, Svensson AM, Kosiborod M, Pivodic A, Gudbjörnsdottir S, Wedel H, Clements M, Dahlqvist S, Lind M. Excess Mortality among Persons with Type 2 Diabetes. N Engl J Med. 2015 Oct 29;373(18):1720-32. doi: 10.1056/NEJMoa1504347.</citation>
    <PMID>26510021</PMID>
  </reference>
  <reference>
    <citation>Simmons RK, Griffin SJ, Lauritzen T, Sandbæk A. Effect of screening for type 2 diabetes on risk of cardiovascular disease and mortality: a controlled trial among 139,075 individuals diagnosed with diabetes in Denmark between 2001 and 2009. Diabetologia. 2017 Nov;60(11):2192-2199. doi: 10.1007/s00125-017-4299-y. Epub 2017 Aug 23.</citation>
    <PMID>28831539</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 27, 2021</study_first_submitted>
  <study_first_submitted_qc>February 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endocrine disorders</keyword>
  <keyword>MCG</keyword>
  <keyword>Cardiovascular disease</keyword>
  <keyword>ischemia</keyword>
  <keyword>CardioFlux</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocrine System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

